Shorter Androgen Blockade for High-Risk Prostate Cancer Patients Treated with Radiotherapy: Trial Results

Reducing ADT from 36 to 18 months Improves Quality of Life, Does Not Reduce Survival

A randomized Phase III Trial of outcomes for high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 months of androgen deprivation therapy has found “no difference in survival between the two groups, with the 18-month group experiencing a better quality of life.”

Survival and biochemical failure rates between 36 months and 18 months of ADT combined with Radiotherapy for men with high-risk prostate. cancer ).

Continue reading “Shorter Androgen Blockade for High-Risk Prostate Cancer Patients Treated with Radiotherapy: Trial Results”

Androgen-deprivation therapy before radical surgery for prostate cancer may harm a subset of patients, help others, study suggests

A study from Japan suggests that men should probably avoid androgen blockade before prostate surgery if they are above 65 or have low testosterone levels.

This round of treatment, known as neoadjuvant ADT, may be prescribed with a view to improving odds for patients who have some adverse markers.

Led by¬† Prof. Masatoshi Eto, the Japanese team analyzed results for 711 patients with clinically localized prostate cancer who were treated with radical prostatectomy (RP) between 2000 and 2013. Some patients underwent androgen deprivation therapy before the surgery, some did not. Continue reading “Androgen-deprivation therapy before radical surgery for prostate cancer may harm a subset of patients, help others, study suggests”